AIDX

20/20 Biolabs Inc

0.6240

Aug 28 • 3:59 PM ET +0.0043 (0.69%)

0.6332

Aftermarket • 7:49 PM ET +0.0092 (1.47%)

Healthcare Medical Devices USA Nano NASD

Peers: ICCM NXL PMI SINT TRIB VVOS XAIR ADGM IRIX NUWE

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	7.97M
Enterprise Value	5.53M
Income	-7.01M
Sales	2.04M
Book/sh	0.13
Cash/sh	0.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Feb 19, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	3.91
P/B	4.72
P/C	1.75
P/FCF	-
EV/EBITDA	-
EV/Sales	2.71
Quick Ratio	1.95
Current Ratio	1.99
Debt/Eq	0.18
LT Debt/Eq	0.12
Option/Short	No / Yes

EPS (ttm)	-0.72
EPS next Y	-0.38
EPS next Q	-0.06
EPS this Y	44.74%
EPS next Y	9.52%
EPS next 5Y	17.29%
EPS past 3/5Y	- 3.60%
Sales past 3/5Y	-43.03% -2.58%
EPS Y/Y TTM	-257.17%
Sales Y/Y TTM	-
EPS Q/Q	-206.97%
Sales Q/Q	31.91%
Earnings	Aug 17 BMO
EPS/Sales Surpr.	-116.67% 14.87%

Insider Own	33.61%
Insider Trans	0.00%
Inst Own	4.23%
Inst Trans	4.49%
ROA	-
ROE	-
ROIC	-164.30%
Gross Margin	31.52%
Oper. Margin	-215.69%
Profit Margin	-343.43%
SMA20	22.98%
SMA50	17.15%
SMA200	-62.63%
Trades

Shs Outstand	12.25M
Shs Float	8.48M
Short Float	1.25%
Short Ratio	0.16
Short Interest	0.11M
52W High	50.00 -98.75%
52W Low	0.40 55.57%
Volatility	10.43% 11.12%
ATR (14)	0.06
RSI (14)	63.09
Beta	-
Rel Volume	0.19
Avg Volume	646.95K
Volume	121,862

Perf Week	12.57%
Perf Month	55.57%
Perf Quarter	-28.02%
Perf Half Y	-83.66%
Perf YTD	-98.75%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	5.00
Prev Close	0.62
Price	0.62
Change %	0.69%

Aug-28-26 06:26PM	20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest Revenue and Expanding Commercial Opportunity (GlobeNewswire)
Aug-26-26 08:31AM	20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest Revenue and Expanding Commercial Opportunity (GlobeNewswire) +6.59%
Aug-17-26 08:31AM	20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level (GlobeNewswire)
Jul-30-26 08:31AM	20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development Tour (GlobeNewswire) -8.49%
Jul-27-26 04:30PM	20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy (GlobeNewswire) -8.31%
08:31AM	Loading…
Jul-23-26 08:31AM	20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock (GlobeNewswire) -6.76%
Jul-09-26 04:01PM	20/20 BioLabs Highlights Investor Webinar Focused on OneTest for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth (GlobeNewswire)
Jun-22-26 04:45PM	20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month (GlobeNewswire) -6.85%
May-27-26 08:31AM	20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters (GlobeNewswire)
May-22-26 08:31AM	20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand (GlobeNewswire) -18.67%
May-20-26 04:05PM	20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress (GlobeNewswire) -6.59%
07:30AM	Sidoti Events, LLC's May Micro-Cap Virtual Conference (ACCESSWIRE)
May-14-26 08:31AM	20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026 (GlobeNewswire)
May-12-26 08:31AM	20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina (GlobeNewswire) +6.33%
Apr-13-26 07:00AM	HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference (TMX Newsfile)
08:31AM	Loading…
Apr-07-26 08:31AM	20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest for Cancer Through Evexia Platform (GlobeNewswire) -5.45%
Mar-31-26 04:57PM	20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress (GlobeNewswire) +5.62%
Mar-27-26 08:31AM	Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest Multi-Cancer Early Detection Blood Test (GlobeNewswire)
Mar-24-26 08:31AM	20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program (GlobeNewswire) -17.59%
Mar-19-26 07:00AM	HEALWELL AI Delivers Record Revenue and First Year of Positive Adjusted EBITDA as Global AI Platform Strategy Takes Hold (TMX Newsfile) -5.05%
Mar-12-26 08:31AM	20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies (GlobeNewswire) -8.49%
Feb-25-26 08:31AM	20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities (GlobeNewswire) -28.82%
Feb-20-26 08:31AM	20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time (GlobeNewswire) -38.04%
Feb-19-26 09:00AM	20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth (GlobeNewswire)

20/20 Biolabs, Inc. engages in development and commercialization of proteomics product line. Its products include One Test, PAULA's Test and BioCheck Suspisious Powder Testing Kit. The company was founded by Jonathan Cohen in May 2000 and is headquartered in Gaithersburg, MD.

FounderMr. Jonathan Cohen

Chief Operating OfficerDr. Jiming Zhou Ph.D.

Chief Scientific OfficerDr. Michael Saul Lebowitz Ph.D.

Chief Financial OfficerMr. Alan B. Bergman

Director of SalesMr. David Lees

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIDX

20/20 Biolabs Inc

Upgrade your Finviz experience